Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Almotriptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D known ✓ | P28221 | 5/20 | 0.58 |
| ▸ | HTR1B known ✓ | P28222 | 4/20 | 0.58 |
| ▸ | HTR1F known ✓ | P30939 | 1/20 | 0.58 |
| ▸ | HTR1A | P08908 | 7/20 | 0.86 |
| ▸ | HTR2A | P28223 | 4/20 | 0.86 |
| ▸ | HTR2B | P41595 | 2/20 | 0.86 |
| ▸ | LMNA | P02545 | 1/20 | 0.86 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.86 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.86 |
| ▸ | HTR5A | P47898 | 9/20 | 0.58 |
| ▸ | HTR2C | P28335 | 2/20 | 0.58 |
| ▸ | HTR1E | P28566 | 1/20 | 0.58 |
| ▸ | HTR7 | P34969 | 1/20 | 0.58 |
| ▸ | HTR3A | P46098 | 1/20 | 0.58 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Almotriptan SCHEMBL1774275 | 0.94 | HTR1A (0.90) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL1957 | 0.93 | HTR1A (1.00) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL29396422 | 0.93 | HTR1A (1.00) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL3273179 | 0.93 | HTR1A (1.00) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL2166 | 0.92 | HTR1A (0.98) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| SCHEMBL1437 | 0.92 | HTR1A (0.98) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL221132 | 0.91 | HTR1A (0.85) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL1848914 | 0.91 | HTR1A (0.85) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL2259962 | 0.91 | HTR1A (0.85) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL5042399 | 0.91 | HTR1A (0.96) | HTR1AHTR2AHTR2BLMNAADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010113183-A2 | PROCESS FOR THE PREPARATION OF 1-[[[3-[2-(DIMETHYLAMINO)ETHYL]-1H-INDOL-5-YL]METHYL]SULFONYL] PYRROLIDINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES LIMITED (IN) | 2010-10-07 | — | — | WO | claimed |
| WO-2012085723-A1 | A PROCESS FOR THE PURIFICATION OF ALMOTRIPTAN ACID ADDITION SALT | ORCHID CHEMICALS AND PHARMACEUTICALS LIMITED (IN) | 2012-06-28 | — | — | WO | disclosed |
| WO-2010113183-A3 | PROCESS FOR THE PREPARATION OF 1-[[[3-[2-(DIMETHYLAMINO)ETHYL]-1H-INDOL-5-YL]METHYL]SULFONYL] PYRROLIDINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES LIMITED (IN) | 2010-12-29 | — | — | WO | disclosed |
| US-20100292290-A1 | NOVEL PROCESS TO PREPARE ALMOTRIPTAN | MYLAN DEVELOPMENT CENTRE PRIVATE LIMITED (IN) | 2010-11-18 | — | — | US | disclosed |
| WO-2010113183-A2 | PROCESS FOR THE PREPARATION OF 1-[[[3-[2-(DIMETHYLAMINO)ETHYL]-1H-INDOL-5-YL]METHYL]SULFONYL] PYRROLIDINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES LIMITED (IN) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010113183-A2 | PROCESS FOR THE PREPARATION OF 1-[[[3-[2-(DIMETHYLAMINO)ETHYL]-1H-INDOL-5-YL]METHYL]SULFONYL] PYRROLIDINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES LIMITED (IN) | 2010-10-07 | — | — | WO | disclosed |
| CN-101842352-A | Novel process | GENERICS UK LTD | 2010-09-22 | — | — | CN | disclosed |
| EP-2170824-A1 | NOVEL PROCESS | Generics Ýuk¨Limited (GB) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009016414-A1 | NOVEL PROCESS | GENERICS [UK] LIMITED (GB) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292290-A1 | NOVEL PROCESS TO PREPARE ALMOTRIPTAN | HTR5A, LPXN, AGPAT5 | HTR1D 84/4885HTR1B 68/4885HTR1F 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.